scholarly journals Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virusassociated Cirrhosis

Gut and Liver ◽  
2020 ◽  
Author(s):  
Seung Kak Shin ◽  
Hyung Joon Yim ◽  
Jeong Han Kim ◽  
Chan Uk Lee ◽  
Jong Eun Yeon ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Virological Response ◽  
Partial Virological Response

Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment

2020 ◽  
Vol 27 (7) ◽  
pp. 731-738 ◽  
Author(s):  
Ya‐Chao Tao ◽  
Meng‐Lan Wang ◽  
Dong‐Mei Zhang ◽  
Dong‐Bo Wu ◽  
Yong‐Hong Wang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Drug Administration ◽  
Virological Response ◽  
Optimal Drug ◽  
Partial Virological Response

Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy

2016 ◽  
Vol 50 (4) ◽  
pp. 338-344 ◽  
Author(s):  
Kevin T. Chaung ◽  
Connor O’Brien ◽  
Nghiem B. Ha ◽  
Nghia H. Nguyen ◽  
Huy N. Trinh ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Alternative Therapies ◽  
Partial Virological Response

scholarly journals Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization

2021 ◽  
Vol 11 ◽  
Author(s):  
Meng Jin ◽  
Yong Chen ◽  
Shuifang Hu ◽  
Meiyan Zhu ◽  
Yan Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Antiviral Therapy ◽  
Virological Response ◽  
Cox Regression ◽  
Intermediate Stage ◽  
Hbv Dna ◽  
Rank Test ◽  
B Virus

IntroductionRole of response to antiviral therapies on survival of patients with intermediate-stage hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) undergoing transarterial chemoembolization (TACE) remains unknown. We aimed to determine whether virological response (VR) or prolonged maintained virological response (MVR) to nucelos(t)ide analogues (NA) therapy could result in improved survival in HBV-HCC patients receiving TACE.MethodsBetween January 2012 and October 2018, data of patients with intermediate HBV-HCC who underwent TACE and started NA therapy within one week prior to TACE treatment at our institution were reviewed. Overall survival (OS) was compared using the Kaplan-Meier method with log-rank test between different VR status groups. Univariable and multivariable Cox regression analyses were used to determine the association between achievement of VR or MVR and OS. VR was defined as an undetectable HBV DNA level (<100 IU/ml) on two consecutive measurements during NA treatment. MVR was defined as a persistently undetectable HBV DNA level after achieving a VR.ResultsA total of 1265 patients undergoing TACE with a median follow-up time of 18 months (range, 2-78 months) were included in the analysis. Of 1265 NA-treated patients [1123 (88.8%) male, median (range) age, 56 (18-75) years], 744 patients (58.8%) achieved VR and the remaining patients (41.2%) did not. Patients with achievement of VR showed a significantly longer OS than those without VR (median OS: 21 vs 16 months; HR, 0.707; 95% CI, 0.622-0.804; P<0.001). Among patients with VR, MVR was present in 542 patients (72.8%), while the other 202 patients (27.2%) in the non-MVR group. The OS for the MVR group was significantly higher than the non-MVR group (median OS: 23.2 vs 18 months; HR, 0.736; 95% CI, 0.612-0.885; P=0.001). Additionally, patients with MVR status more than two years showed a better OS than those with just one-year (HR, 0.719; 95% CI, 0.650-0.797; P<0.001) or one-to-two-year MVR (HR, 0.612; 95% CI, 0.471-0.795; P=0.024). On multivariable analyses, splenomegaly and up-to-seven criteria were independent prognostic factors of OS in both VR and MVR cohorts.ConclusionsIn patients with intermediate-stage HBV-HCC, both VR to antiviral therapy and prolonged response are associated with prolonged OS after TACE, especially for those within up-to-seven criteria.

Partial Virological Response to Adefovir Add-On Lamivudine Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B

Digestion ◽  
2013 ◽  
Vol 87 (3) ◽  
pp. 196-203 ◽  
Author(s):  
Young Eun Chon ◽  
Jun Yong Park ◽  
Sang Hoon Ahn ◽  
Do Young Kim ◽  
Kwang-Hyub Han ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Rescue Therapy ◽  
Partial Virological Response

Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B

2011 ◽  
Vol 16 (4) ◽  
pp. 469-477 ◽  
Author(s):  
Young Eun Chon ◽  
Seung Up Kim ◽  
Chun Kyon Lee ◽  
Jeong Heo ◽  
Ja Kyung Kim ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Virological Response ◽  
Treatment Naïve ◽  
Partial Virological Response
Sign in / Sign up

Export Citation Format

Share Document